A medical device trial rarely looks like a typical drug trial's budget problem scaled down. Device studies are frequently shorter, move faster from first enrollment to completion, and because device approval often depends on demonstrating performance across multiple healthcare systems and reimbursement environments at once commonly run across several countries simultaneously in support of a single global submission. Budget software built primarily around a single-country, multi-year pharma trial model misses several of the things that actually matter for this pattern.
Running a device trial across multiple countries means tracking budgets, payments, and currencies that don't behave uniformly different site payment norms, different currencies, different regulatory expectations for financial documentation in each market.
A platform built around single-country trial finance can technically be used for a multi-country study, but it wasn't designed around the core question a device sponsor actually needs answered: what's our consolidated financial position across every country and currency, right now, without manually converting and reconciling each one by hand.
Device trials often move from first patient in to completion faster than a typical multi-year drug trial, which means budget setup, site payment configuration, and milestone tracking need to be operational quickly, not assembled over the kind of extended implementation timeline a slower-moving pharma trial can absorb.
A budget platform that takes months to configure is fighting against the actual pace of the trial it's meant to support.
Device studies, especially post-market surveillance and registry studies, frequently use payment structures that don't map cleanly onto the standard per-visit, per-milestone model built for drug trials per-patient fees, ongoing surveillance payments, and registry-based compensation are common.
Budget software rigid around one payment logic forces workarounds for exactly the payment patterns device trials actually use.
Financial documentation supporting a device submission needs to hold up under the specific expectations of device regulatory review, including 21 CFR Part 11 requirements for electronic records and signatures where applicable.
A platform that treats compliance as a generic checkbox rather than a built-in property of every payment record creates real risk at exactly the point where financial documentation gets scrutinized during submission review.
| Built Primarily for Drug Trials | What a Device Trial Needs | |
|---|---|---|
| Multi-country visibility | Often single-country by default | Consolidated view across countries and currencies |
| Setup speed | Assumes a longer trial timeline to absorb it | Needs to be operational quickly, matching faster trial pace |
| Payment structures | Standard per-visit, per-milestone logic | Flexible enough for per-patient, registry, and surveillance models |
| Compliance documentation | Generic | Built around 21 CFR Part 11 expectations by default |
Cloudbyz CTFM provides multi-currency, multi-country financial visibility natively, so a device sponsor running a global study sees one consolidated financial picture rather than reconciling separate country-level views by hand.
It's built on a platform that supports 21 CFR Part 11-ready documentation as a standard property of payment records, not an added-on compliance layer.
How closely this matches a specific device program depends on its exact country footprint and payment structure but multi-country consolidation, setup speed, payment flexibility, and built-in compliance are the four factors actually worth evaluating, more than a general trial budget feature list built with a different kind of trial in mind.
Book a demo with Cloudbyz team.